 |
|
|
| |
Frequencies of Resistance-Associated Amino Acid Variants Following Combination Treatment with Boceprevir Plus PEGINTRON (PegInterferon Alfa-2b)/Ribavirin in Patients With Chronic Hepatitis C (CHC), Genotype 1 (G1)
|
| |
| |
Reported by Jules Levin
AASLD Nov 1 2010 Boston
John M. Vierling1, Paul Y. Kwo2, Eric J. Lawitz3, Jonathan McCone4, Eugene R. Schiff5, David Pound6, Mitchell N. Davis7, Joseph S. Galati8, Stuart C. Gordon9, Natarajan Ravendhran10, Lorenzo Rossaro11, Frank H. Anderson12, Ira M. Jacobson13, Raymond Rubin14, Lisa D. Pedicone15, Eirum Chaudhri15, Xiao Tong15, Ping Qiu15, Richard J.O. Barnard15, Clifford A. Brass15, Janice K. Albrecht15, Patricia Mendez15, and Robert Ralston15
1Baylor College of Medicine, Houston, TX; 2Indiana University School of Medicine, Indianapolis, IN; 3Alamo Medical Research, San Antonio, TX; 4Mt. Vernon Endoscopy Center, Alexandria, VA; 5University of Miami, Miami, FL;6Indianapolis Gastroenterology Research Foundation, Indianapolis, IN; 7DigestiveCARE-South Florida Center of Gastroenterology, Wellington, FL; 8Liver Specialists of Texas, Houston, TX; 9Henry Ford Hospital, Detroit, MI;10University of Maryland Medical System and Digestive Disease Associates, Baltimore, MD; 11University of California-Davis Medical Center, Sacramento, CA; 12Liver and Intestinal Research Centre, Vancouver, British Columbia, Canada; 13Weill Cornell Medical College, New York, NY; 14Liver Center of Atlanta, Atlanta, GA; 15Merck, Whitehouse Station, NJ
|
| |
|
|
|
|
|
